You are here

  • Home
  • Archive
  • Volume 104, Issue 3
  • Exposure to acid-suppressing medications in the first 6 months of life is associated with an increased risk of allergic disease diagnosis

Article Text

Article menu
Download PDFPDF
Structured abstracts of sentinel articles: Picket
Exposure to acid-suppressing medications in the first 6 months of life is associated with an increased risk of allergic disease diagnosis
  1. Rebecca Amy Dalrymple
  1. Correspondence to Dr Rebecca Amy Dalrymple, Acorn Center, Vale of Leven District General Hospital, Alexandria G83 0UA, UK; rebecca.dicks{at}doctors.org.uk

https://doi.org/10.1136/archdischild-2018-316273

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Design: A retrospective cohort study.1

    Setting: The children of US service personnel identified from the TRICARE Management Activity database. This database holds information on the billing records for inpatient care, outpatient care and outpatient pharmacy use of military personnel.

    Patients: 792 130 infants were recruited within the first 35 days of life, between 2001 and 2013. They were excluded if they were diagnosed with an allergic condition in the first 6 months of life, or if they had a neonatal stay of more than 7 days.

    Exposure factor: Children prescribed a histamine-2 receptor antagonist (H2RA), proton pump inhibitor (PPI) or antibiotic within …

    View Full Text

    Footnotes

    • Contributors RAD wrote the abstract and commentary.

    • Provenance and peer review Not commissioned; internally peer reviewed.